Cargando…

Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development

In 2017, the World Health Organization (WHO) named A. baumannii as one of the three antibiotic-resistant bacterial species on its list of global priority pathogens in dire need of novel and effective treatment. With only polymyxin and tigecycline antibiotics left as last-resort treatments, the need...

Descripción completa

Detalles Bibliográficos
Autores principales: Mat Rahim, NorAziyah, Lee, HaiYen, Strych, Ulrich, AbuBakar, Sazaly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437540/
https://www.ncbi.nlm.nih.gov/pubmed/34106809
http://dx.doi.org/10.1080/21645515.2021.1927412
_version_ 1783752178779815936
author Mat Rahim, NorAziyah
Lee, HaiYen
Strych, Ulrich
AbuBakar, Sazaly
author_facet Mat Rahim, NorAziyah
Lee, HaiYen
Strych, Ulrich
AbuBakar, Sazaly
author_sort Mat Rahim, NorAziyah
collection PubMed
description In 2017, the World Health Organization (WHO) named A. baumannii as one of the three antibiotic-resistant bacterial species on its list of global priority pathogens in dire need of novel and effective treatment. With only polymyxin and tigecycline antibiotics left as last-resort treatments, the need for novel alternative approaches to the control of this bacterium becomes imperative. Vaccines against numerous bacteria have had impressive records in reducing the burden of the respective diseases and addressing antimicrobial resistance; as in the case of Haemophilus influenzae type b . A similar approach could be appropriate for A. baumannii. Toward this end, several potentially protective antigens against A. baumannii were identified and evaluated as vaccine antigen candidates. A licensed vaccine for the bacteria, however, is still not in sight. Here we explore and discuss challenges in vaccine development against A. baumannii and the promising approaches for improving the vaccine development process.
format Online
Article
Text
id pubmed-8437540
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84375402021-09-14 Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development Mat Rahim, NorAziyah Lee, HaiYen Strych, Ulrich AbuBakar, Sazaly Hum Vaccin Immunother Review In 2017, the World Health Organization (WHO) named A. baumannii as one of the three antibiotic-resistant bacterial species on its list of global priority pathogens in dire need of novel and effective treatment. With only polymyxin and tigecycline antibiotics left as last-resort treatments, the need for novel alternative approaches to the control of this bacterium becomes imperative. Vaccines against numerous bacteria have had impressive records in reducing the burden of the respective diseases and addressing antimicrobial resistance; as in the case of Haemophilus influenzae type b . A similar approach could be appropriate for A. baumannii. Toward this end, several potentially protective antigens against A. baumannii were identified and evaluated as vaccine antigen candidates. A licensed vaccine for the bacteria, however, is still not in sight. Here we explore and discuss challenges in vaccine development against A. baumannii and the promising approaches for improving the vaccine development process. Taylor & Francis 2021-06-09 /pmc/articles/PMC8437540/ /pubmed/34106809 http://dx.doi.org/10.1080/21645515.2021.1927412 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Review
Mat Rahim, NorAziyah
Lee, HaiYen
Strych, Ulrich
AbuBakar, Sazaly
Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development
title Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development
title_full Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development
title_fullStr Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development
title_full_unstemmed Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development
title_short Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development
title_sort facing the challenges of multidrug-resistant acinetobacter baumannii: progress and prospects in the vaccine development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437540/
https://www.ncbi.nlm.nih.gov/pubmed/34106809
http://dx.doi.org/10.1080/21645515.2021.1927412
work_keys_str_mv AT matrahimnoraziyah facingthechallengesofmultidrugresistantacinetobacterbaumanniiprogressandprospectsinthevaccinedevelopment
AT leehaiyen facingthechallengesofmultidrugresistantacinetobacterbaumanniiprogressandprospectsinthevaccinedevelopment
AT strychulrich facingthechallengesofmultidrugresistantacinetobacterbaumanniiprogressandprospectsinthevaccinedevelopment
AT abubakarsazaly facingthechallengesofmultidrugresistantacinetobacterbaumanniiprogressandprospectsinthevaccinedevelopment